Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
dc.contributor.author | Reck, M | |
dc.contributor.author | Kerr, KM | |
dc.contributor.author | Grohe, C | |
dc.contributor.author | Manegold, C | |
dc.contributor.author | Pavlakis, N | |
dc.contributor.author | Paz-Ares, L | |
dc.contributor.author | Huber, RM | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Thatcher, Nick | |
dc.contributor.author | Park, K | |
dc.contributor.author | Hilberg, F | |
dc.contributor.author | Barrueco, J | |
dc.contributor.author | Kaiser, R | |
dc.date.accessioned | 2019-03-29T14:22:23Z | |
dc.date.available | 2019-03-29T14:22:23Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Reck M, Kerr KM, Grohe C, Manegold C, Pavlakis N, Paz-Ares L, et al. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? Future Oncol. 2019 Feb 13. | en |
dc.identifier.pmid | 30758227 | en |
dc.identifier.doi | 10.2217/fon-2018-0948 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621621 | |
dc.description.abstract | Abstract A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6-9 months of first-line treatment initiation. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.2217/fon-2018-0948 | en |
dc.title | Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? | en |
dc.type | Article | en |
dc.contributor.department | Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany | en |
dc.identifier.journal | Future Oncology | en |
dc.description.note | en] |